Skip to main content
Universal Drugstore logo

Why pay full price for medications?

See Prices Now

Does Adbry Cause Weight Gain?

What Clinical Research Shows About This Eczema Treatment

Clinical trials and FDA-approved prescribing information do not identify weight gain as a common or established side effect of Adbry (tralokinumab-ldrm). While a small number of patients have reported weight changes after starting this eczema medication, current evidence does not prove that Adbry causes weight gain.

Shop Medications

This atopic dermatitis treatment works by blocking interleukin-13, a protein that drives inflammation in eczema. Understanding the relationship between Adbry and body weight requires examining both controlled clinical trial data and real-world patient experiences to separate proven effects from coincidental changes.

In This Article

What Do Clinical Trials Show About Adbry and Weight Gain?

Controlled clinical trials involving thousands of patients with moderate to severe atopic dermatitis found no evidence that Adbry causes weight gain. In these studies, adverse event rates were similar between patients receiving Adbry and those receiving placebo injections during the initial treatment period.

A pooled analysis of five clinical trials specifically evaluated Adbry’s safety profile and found the medication was generally well tolerated. Weight gain was not highlighted as a treatment-related safety signal in this comprehensive review. The most commonly reported side effects were injection site reactions, eye infections like conjunctivitis, and upper respiratory tract infections.

Why Pay Full Price?

Search our full medication catalogue and save up to 80% - no insurance needed.

See Prices Now

Long-term safety data spanning up to 4.5 years of treatment showed no new safety signals emerging over extended use. Importantly, adverse event rates did not increase with longer treatment duration, and weight gain was not identified as a concern during extended monitoring.

Have Any Patients Reported Weight Gain While Taking Adbry?

Some patients have reported weight gain after starting Adbry, but these isolated reports cannot prove the medication caused the weight change. In one real-world clinical study following 84 adults treated with Adbry for 28 weeks, only one participant (1.2%) reported weight gain during treatment.

Real-world pharmacovigilance studies have identified several potential adverse reactions not emphasized in the original product labeling, including dizziness, headache, nausea, and hair loss. However, these studies have not established weight gain as a confirmed causal adverse effect of Adbry treatment.

The key limitation with post-market reports is that they cannot determine whether Adbry, another medical condition, dietary changes, reduced physical activity, or other factors contributed to any observed weight changes. Correlation does not equal causation in these observational reports.

How Does Body Weight Affect Adbry Treatment?

Body weight influences how much Adbry circulates in your system, but this is different from Adbry causing weight gain. The FDA prescribing information notes that drug exposure changes with body weight, which describes how the medication is processed rather than suggesting the medication affects patient weight.

This pharmacokinetic relationship means that patients with higher body weight may have lower blood levels of the medication, while those with lower body weight may have higher levels. Healthcare providers consider this when determining appropriate dosing schedules, but it does not indicate that Adbry treatment leads to weight changes.

The standard Adbry dosing regimen accounts for these pharmacokinetic differences. Most patients receive 300 mg injections every two weeks initially, then may transition to monthly dosing based on their response and body weight considerations.

What Are the Most Common Side Effects of Adbry?

The most frequently reported side effects of Adbry are injection site reactions, upper respiratory tract infections, and conjunctivitis (eye inflammation). These effects were observed consistently across multiple clinical trials and occur more commonly than any reports of weight changes.

Injection site reactions typically include redness, swelling, or pain at the injection location and usually resolve within a few days. Upper respiratory infections may present as cold-like symptoms, while conjunctivitis involves eye redness, itching, or discharge that should be evaluated by a healthcare provider.

Other reported side effects include keratoconjunctivitis (inflammation affecting both the cornea and conjunctiva) and allergic conjunctivitis. These eye-related effects occur because the same inflammatory pathways that Adbry targets in skin eczema also play roles in eye health.

Should You Be Concerned About Weight Changes on Adbry?

Unexpected weight gain while taking Adbry warrants discussion with your healthcare provider, but the medication itself is unlikely to be the cause based on current evidence. Weight changes can result from many factors, including dietary modifications, activity level changes, other medications, or underlying health conditions that may be unrelated to your eczema treatment.

Keep track of any significant weight changes (generally considered 5 pounds or more over a short period) and report them during your regular medical appointments. Your doctor can help determine whether the change might be related to Adbry, other medications you are taking, or separate health factors that need attention.

Do not stop Adbry treatment without medical guidance if you notice weight changes. Abruptly discontinuing eczema medication can lead to symptom flare-ups that may be more concerning than modest weight fluctuations. Your healthcare provider can evaluate the situation and adjust your treatment plan if needed.

How Does Adbry Compare to Other Eczema Medications for Weight Effects?

Adbry appears similar to other biologic eczema treatments in terms of weight-related effects, with no strong evidence linking any of these medications to significant weight gain. Dupixent (dupilumab), another commonly prescribed biologic for atopic dermatitis, also does not list weight gain among its established side effects in clinical trial data.

Traditional eczema treatments like topical corticosteroids or oral immunosuppressants may have different side effect profiles, but systemic weight gain is not typically associated with the targeted biologic therapies used for moderate to severe atopic dermatitis.

The choice between different eczema medications should be based on factors like treatment effectiveness, injection frequency, cost considerations, and individual patient response rather than concerns about weight gain, given the lack of evidence supporting this as a common effect with Adbry.

References

Related Conditions